Axplora announces €50 million investment at Mourenx to advance API manufacturing
Raubling (Germany), 12 February 2025 – Axplora, a global leader in API small molecule and ADC manufacturing, is proud to announce a landmark €50 million investment being made at its Mourenx site in Southwest France by one of its customers. This investment secures Mourenx’s position as a key player in the fight against cardiovascular and metabolic diseases. Specializing in large-scale API industrial chemistry and chromatography, this transformative project will enhance Mourenx’s capabilities, positioning it as a center of excellence in the Axplora network for contract manufacturing of APIs and drug substances for FDA-approved biologics.
This investment underscores Axplora’s commitment to partnering with leading pharmaceutical companies, fostering innovation, supporting local economic growth, and delivering life-changing therapies to patients worldwide. By upgrading Mourenx’s infrastructure and capabilities, Axplora will further strengthen its expertise in peptide purification in a biologics environment, supporting the development of next-generation therapies, including GLP-1 drugs that target diabetes and obesity—some of society’s most urgent health challenges.
"GLP-1 therapies represent a paradigm shift in medicine, offering targeted treatments for complex diseases with unprecedented efficacy and tolerability,” said Arul Ramadurai, Chief Commercial Officer. “This initiative, built on strong customer partnerships, reinforces Axplora’s role as a trusted partner in manufacturing life-changing, breakthrough medicines.”
Dr Pere Patón-Morales, Chief Operating Officer, said:
This project is a testament to our pioneering expertise in industrial chromatography, and working closely with our client, we are targeting having the facility BLA-ready in 15 months. Our internal teams are collaborating with partners in a strong cross-functional project team, well-supported by the local authorities. We are looking forward to a bright future at Mourenx.
Construction and infrastructure development will begin immediately, with first supplies of GLP-1 therapies expected in 2026. This investment ensures the Mourenx site will remain a key contributor to Axplora’s API network well into the 2030s and beyond.
